Sugi Predict

Sugi Predict / Compounds / SCHEMBL119225

SCHEMBL119225

SCHEMBL119225

FC(F)(F)c1cc(Cl)ccc1CBr

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLQ O75417 1/20 0.46
▸ NOS3 P29474 1/20 0.40
▸ NOS1 P29475 1/20 0.40
▸ NOS2 P35228 1/20 0.40
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ GPR183 P32249 1/20 0.39
▸ SLC6A4 P31645 3/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ IDO1 P14902 3/20 0.37
▸ P2RX7 Q99572 3/20 0.36
▸ HTT P42858 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ PAX8 Q06710 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29465609 1.00 POLQ (0.46) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL1125472 0.88 NOS3 (0.47) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL27851289 0.85 POLQ (0.43) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL11603196 0.83 POLQ (0.48) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL12682526 0.82 POLQ (0.50) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL7804289 0.82 POLQ (0.47) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL805479 0.80 POLQ (0.52) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL1693375 0.80 POLQ (0.46) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL192931 0.80 POLQ (0.46) POLQNOS3NOS1NOS2CYP1A2
SCHEMBL30098378 0.80 POLQ (0.46) POLQNOS3NOS1NOS2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570642-B2 GLP-IR modulating compounds GILEAD SCIENCES, INC. (US) 2026-03-10 — — US disclosed
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-20 — — US disclosed
US-11858918-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2024-01-02 — — US disclosed
CN-117279905-A Carboxy-benzimidazole GLP-1R modulating compounds 吉利德科学公司 2023-12-22 — — CN disclosed
US-20230102927-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-03-30 — — US disclosed
CN-114507220-B Substituted 4-phenyl-5-functionalized 1,2, 4-triazole derivative and preparation method and application thereof 中国医学科学院医药生物技术研究所 2023-01-10 — — CN disclosed
CN-109963836-B Deuterium atom substituted indole carboxamide derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-11-22 — — CN disclosed
CN-109485595-B Hydrophilic group substituted indole formamide derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-05-27 — — CN disclosed
CN-114507220-A Substituted 4-phenyl-5-functionalized 1,2, 4-triazole derivative and preparation method and application thereof 中国医学科学院医药生物技术研究所 2022-05-17 — — CN disclosed
CN-113227048-B Crystal form of indole carboxamide derivative and preparation method thereof 江苏恒瑞医药股份有限公司 2022-04-12 — — CN disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 — — WO disclosed
WO-2010122089-A1 N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS GLAXO GROUP LIMITED (GB) 2010-10-28 — — WO disclosed
US-20100273744-A1 COMPOUNDS GORE PAUL MARTIN 2010-10-28 — — US disclosed
WO-2008137102-A2 METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR TORREYPINES THERAPEUTICS, INC. (US) 2008-11-13 — — WO disclosed
US-20070043057-A1 Lonidamine analogs THRESHOLD PHARMACEUTICALS, INC. (US) 2007-02-22 — — US disclosed
US-20070043057-A1 Lonidamine analogs THRESHOLD PHARMACEUTICALS, INC. (US) 2007-02-22 — — US disclosed
US-20070043057-A1 Lonidamine analogs THRESHOLD PHARMACEUTICALS, INC. (US) 2007-02-22 — — US disclosed
US-20070015771-A1 Lonidamine analogs THRESHOLD PHARMACEUTICALS, INC. (US) 2007-01-18 — — US disclosed
US-20070015771-A1 Lonidamine analogs THRESHOLD PHARMACEUTICALS, INC. (US) 2007-01-18 — — US disclosed
US-20070015771-A1 Lonidamine analogs THRESHOLD PHARMACEUTICALS, INC. (US) 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015771-A1 Lonidamine analogs LONP1, LPXN, QDPR POLQ 1046/4885NOS3 3190/4885NOS1 3403/4885
US-11858918-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 POLQ 4471/4885NOS3 2981/4885NOS1 3506/4885
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 POLQ 4471/4885NOS3 2981/4885NOS1 3506/4885
US-20070043057-A1 Lonidamine analogs LONP1, LPXN, QDPR POLQ 1046/4885NOS3 3190/4885NOS1 3403/4885
US-20230102927-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 POLQ 4471/4885NOS3 2981/4885NOS1 3506/4885
US-20100273744-A1 COMPOUNDS LTC4S, HRH4, HRH2 POLQ 1599/4885NOS3 1039/4885NOS1 1389/4885
US-12570642-B2 GLP-IR modulating compounds GLP1R, GIPR, GPR119 POLQ 4847/4885NOS3 3635/4885NOS1 3864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.